Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1955 1
1964 2
1965 1
1966 3
1967 2
1968 4
1969 3
1970 1
1973 2
1974 1
1975 1
1977 2
1978 7
1979 3
1980 3
1981 6
1982 8
1983 6
1984 1
1985 3
1986 6
1987 3
1988 6
1989 4
1990 7
1991 6
1992 6
1993 4
1994 2
1995 4
1996 4
1997 3
1998 6
1999 6
2000 3
2001 10
2002 11
2003 9
2004 10
2005 7
2006 12
2007 10
2008 18
2009 23
2010 21
2011 24
2012 19
2013 17
2014 20
2015 29
2016 33
2017 21
2018 19
2019 22
2020 19
2021 13
2022 12
2023 26
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Neurotoxicity and Immunotherapy.
Kopecký J. Kopecký J. Klin Onkol. 2020 Winter;33(1):11-14. doi: 10.14735/amko202011. Klin Onkol. 2020. PMID: 32075382 Review. English.
Bioethanol production from microalgae polysaccharides.
Lakatos GE, Ranglová K, Manoel JC, Grivalský T, Kopecký J, Masojídek J. Lakatos GE, et al. Among authors: kopecky j. Folia Microbiol (Praha). 2019 Sep;64(5):627-644. doi: 10.1007/s12223-019-00732-0. Epub 2019 Jul 27. Folia Microbiol (Praha). 2019. PMID: 31352666 Review.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: kopecky j. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
Omega-3 PUFAs prevent bone impairment and bone marrow adiposity in mouse model of obesity.
Benova A, Ferencakova M, Bardova K, Funda J, Prochazka J, Spoutil F, Cajka T, Dzubanova M, Balcaen T, Kerckhofs G, Willekens W, van Lenthe GH, Charyyeva A, Alquicer G, Pecinova A, Mracek T, Horakova O, Coupeau R, Hansen MS, Rossmeisl M, Kopecky J, Tencerova M. Benova A, et al. Among authors: kopecky j. Commun Biol. 2023 Oct 14;6(1):1043. doi: 10.1038/s42003-023-05407-8. Commun Biol. 2023. PMID: 37833362 Free PMC article.
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Poprach A, Kiss I, Stanik M, Barusova T, Pospisilova L, Fiala O, Kopecky J, Richter I, Melichar B, Studentova H, Lakomy R, Holanek M, Rozsypalova A, Zemanková A, Svoboda M, Buchler T. Poprach A, et al. Among authors: kopecky j. Target Oncol. 2023 Nov;18(6):893-903. doi: 10.1007/s11523-023-01013-0. Epub 2023 Nov 13. Target Oncol. 2023. PMID: 37957520
496 results